echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Blood System > NEJM: Efficacy of oral rizabrutinib in the treatment of immune thrombocytopenia

    NEJM: Efficacy of oral rizabrutinib in the treatment of immune thrombocytopenia

    • Last Update: 2022-05-15
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com

    Rizabrutinib is an oral, reversible covalent inhibitor of tyrosine kinases that increases platelet counts in patients with immune


    immunity

    Recently, a research article was published in the top medical journal NEJM.


    In addition, the investigators escalated the dose of rizabrutinib over 24 weeks; the lowest starting dose was 200 mg once daily and the higher starting dose was 400 mg once daily and 300 mg twice daily 400mg


    60 patients were included in the study


    thrombus

    Thus, rizabrutinib was effective at all dose levels and was only associated with low-level toxic effects


    Rizabrutinib was effective at all dose levels and was associated with only low-level toxic effects


    Original Credit: David J.
    Kuter.
    et al.
    Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia .
    NEJM.
    2022.
    https:// Rilzabrutinib, an Oral BTK Inhibitor, in Immune Thrombocytopenia leave a message here



    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.